Blisibimod
B-cell activating factor (BAFF) inhibitor for the potential treatment of B-cell associated renal diseases, including IgA nephropathy.
LATEST NEWS
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura.
Anthera Pharmaceuticals to Present at 30th Annual ROTH Conference.